Abstract and Introduction
On February 26, 2015, the Advisory Committee on Immunization Practices (ACIP) voted that a single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers. ACIP also approved recommendations for at-risk laboratory personnel and certain travelers to receive additional doses of yellow fever vaccine (Box). The ACIP Japanese Encephalitis and Yellow Fever Vaccines Workgroup evaluated published and unpublished data on yellow fever vaccine immunogenicity and safety. The evidence for benefits and risks associated with yellow fever vaccine booster doses was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.[2,3] This report summarizes the evidence considered by ACIP and provides the updated recommendations for yellow fever vaccine booster doses.
Morbidity and Mortality Weekly Report. 2015;64(23):647-650. © 2015 Centers for Disease Control and Prevention (CDC)